- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Aicardi syndrome.
Displaying page 1 of 1.
EudraCT Number: 2014-002710-23 | Sponsor Protocol Number: P140203 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2025-000001-16 | Sponsor Protocol Number: I4V-JE-JAJE | Start Date*: 2025-02-19 | |||||||||||||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||||||||||||
Full Title: A Phase 2/3, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Baricitinib in Adult and Pediatric Japanese Patients with NNS/CANDLE, SAVI, and AGS | |||||||||||||||||||||||
Medical condition: Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature Syndrome, STING-Associated Vasculopathy with Onset in Infancy, Aicardi Goutieres Sy... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000064-21 | Sponsor Protocol Number: TPN-101-AGS-201 | Start Date*: 2022-09-20 | |||||||||||
Sponsor Name:Transposon Therapeutics Inc | |||||||||||||
Full Title: A Phase 2a Study of TPN-101 in Patients with Aicardi-Goutières Syndrome (AGS) | |||||||||||||
Medical condition: Aicardi-Goutières Syndrome (AGS) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003424-31 | Sponsor Protocol Number: I4V-MC-JAGA | Start Date*: Information not available in EudraCT |
Sponsor Name:Eli Lilly and Company | ||
Full Title: Treatment of Conditions Expected to Benefit from JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI, and Severe Juvenile Dermatomyositis | ||
Medical condition: CANDLE, CANDLE-Related Conditions, SAVI, and Severe Juvenile Dermatomyositis, Aicardi-Goutieres Syndrome | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
